[Special Stock] Tomocube Nears International Standard with World's First Core Technology... Five-Year Lead Draws Global Attention

Tomocube is showing strong performance. Expectations that Tomocube's holotomography technology could become an international standard appear to be influencing the stock price.

Professor Hwang Taehyun of Vanderbilt University School of Medicine in the United States stated in an interview with a media outlet, "Since all data used by HTAN is based on Tomocube imaging, the possibility has increased for Tomocube, a domestically developed holotomography technology, to establish itself as an international standard."

Professor Hwang is currently utilizing Tomocube's holotomography technology in the HTAN (Human Tumor Atlas Network) project, which is led by the US National Cancer Institute (NCI). HTAN is a global research network that creates three-dimensional maps of tumors. Professor Hwang is laying the groundwork for this technology to become a 'standard' in the field.

At 12:04 a.m. on the 2nd, Tomocube was trading at 18,810 won, up 15.26% from the previous trading day.

Tomocube is the first company in the world to develop second-generation holotomography (HT) technology, maintaining a technological lead of over five years compared to competitors. Holotomography (HT) enables imaging of three-dimensional objects in a label-free and non-destructive manner, surpassing the limitations of conventional microscopes. The technology is regarded as having limitless potential for applications, and it can be used to pioneer a wide range of new markets.

The '3D Multidimensional Evolution Gastric Cancer Precancerous Map Center' (GAME3D), in which Professor Hwang is a principal researcher, aims to construct a four-dimensional map that goes beyond three dimensions. By applying advanced artificial intelligence (AI) technology to a 3D cancer cell map built with holotomography images that allow real-time, high-resolution observation and imaging of living cells without loss or distortion, the project seeks to add the dimension of time to track changes in cancer cells.

This approach enables the observation and prediction of the occurrence and growth of cancer cells, the process of metastasis, the emergence of variant cancer cells that negatively affect treatment outcomes, and changes in cancer cells in response to anticancer therapy. With the rapid advancement of AI technology, it has become a feasible goal not only to model tumor cell samples for each cancer type but also to build models and maps for every single tumor cell present in each cancer patient.

Professor Hwang explained, "The ultimate goal of this research is also the development of cancer therapeutics," adding, "Ultimately, cancer prevention will also be possible." He went on to say, "The aim is to predict and respond so that variant cells do not develop into cancer or so that cancer cells do not metastasize," and "The same principle can be applied to areas such as the microbiome and cosmetics, including anti-aging fields."

He emphasized, "It is necessary to know the exact location of cancer cells and the roles they play at those locations," and added, "Once this is known, there is already technology that can produce therapeutics in about 18 hours." Furthermore, he introduced, "This will not only reduce the cost and time required for cancer patient diagnosis and treatment, but also enable truly precise, personalized therapies for each patient." He explained, "By analyzing cancer tissue immediately, the most suitable therapeutic and dosage can be identified, and customized anticancer drugs can be individually produced and administered right away."

The movement to skip the animal testing stage, which was previously required before clinical trials for new drug development, is also expected to contribute to the rise in Tomocube's corporate value. The likelihood that toxicity prediction through animal testing will be replaced by other technologies has increased. This is because organoid testing methods are expected to replace animal testing, and the activation of organoids is closely related to holotomography. Tomocube was the first in the world to develop second-generation technology. With just one click, it is possible to image and analyze thick organoids, and the accuracy is also extremely high.